Breaking News Instant updates and real-time market news.

SRPT

Sarepta

$31.82

0.16 (0.51%)

07:35
12/14/16
12/14
07:35
12/14/16
07:35

Jefferies cuts Sarepta target on slower than expected launch

Jefferies analyst Gena Wang cut her price target for Sarepta Therapeutics to $32 from $46 after her due diligence revealed stronger payer pushback and a slower launch for Exondys 51, the company's' recently approved treatment of Duchenne muscular dystrophy. After speaking with four private payers, three Medicaid experts and "several" Duchenne muscular dystrophy experts with "first-hand experience" of Exondys 51, Wang believes the majority of patients being under Medicaid as well as restrictive payer policies could further slow the launch of Exondys 51 in the near term. Based on available data, three of five national and eight of 15 regional managed care organizations have denied or restricted coverage for Exondys 51, the analyst tells investors in a research note. Wang keeps a Hold rating on Sarepta shares.

SRPT Sarepta
$31.82

0.16 (0.51%)

11/11/16
LEER
11/11/16
NO CHANGE
Target $55
LEER
Market Perform
Sarepta Exondys 51 launch expectations seem too high for 2017, says Leerink
Leerink analyst Joseph Schwartz believes Sarepta Exondys 51 launch expectations may be too high for 2017. While nothing that a true Duchenne muscular dystrophy prevalence remains unknown, the analyst says that a "start form" number of about 200 patients would need to be provided in early January in order for investors to be confident in 2017 consensus sales estimates of $215M. Additionally, Schwartz points out that based on the price of Exondys 51 per vial, it currently appears that management has underestimated the true price of the drug which they will realize.
11/29/16
BARD
11/29/16
NO CHANGE
Target $102
BARD
Outperform
Baird sees strong launch for Sarepta after surveying neurologists
After his firm surveyed 30 neurologists treating at least ten Duchenne muscular dystrophy patients and at least five suspected/confirmed patients amenable to exon-51 skipping, Baird analyst Brian Skorney believes Sarepta Therapeutics' Exondys 51 is positioned for a strong launch. In a research note earlier today, Skorney said that most of the 30 doctors surveyed seem convinced of the drug's efficacy, and plan to start prescribing the drug in the next year. The drug's consensus sales estimate for its first quarter on the market of $7.1M may be understating sales, Skorney wrote. The analyst continues to expect $11M of Exondys 51 sales in Q4. He has an Outperform rating on shares of Sarepta with a $102 price target. The stock is up 34c, or 1%, to $36.62 in morning trading.
12/01/16
RBCM
12/01/16
NO CHANGE
RBCM
Outperform
Sarepta DMD drug still likely to be covered by UnitedHealth, says RBC Capital
RBC Capital analyst Simos Simeonidis said some language in UnitedHealthcare's (UNH) Commercial Drug Policy for Sarepta's (SRPT) Exondys 51 may have "spooked" investors, but he continues to believe that the DMD drug will end up being covered by the insurer. The analyst, who would be a buyer of Sarepta amid this weakness, keeps an Outperform rating on the stock.
12/01/16
FBCO
12/01/16
NO CHANGE
FBCO
Outperform
UnitedHealth policy for Exondys 51 a positive for Sarepta, says Credit Suisse
Credit Suisse analyst Alethia Young noted that Sarepta (SRPT) shares have been weak since UnitedHealth (UNH) posted its medical benefit policy for the company's DMD drug Exondys 51, but she doesn't see a reason for the weakness. She doesn't think encouraging home infusions limits access and believes the requirement for an every 6 month reauthorization is neither "prohibitive nor concerning" as it is standard with expensive rare disease treatments. She sees the policy as a positive for Sarepta, as having more payers supporting Exondys reimbursement makes it hard for other payers not to do so, and keeps an Outperform rating on Sarepta shares.

TODAY'S FREE FLY STORIES

FDX

FedEx

$173.53

-0.14 (-0.08%)

17:47
09/17/19
09/17
17:47
09/17/19
17:47
Hot Stocks
FedEx EVP Carere says building 'powerful relationships' with many retailers »

Says forged new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 23

    Sep

  • 30

    Sep

  • 01

    Oct

  • 13

    Nov

UBER

Uber

$34.28

-0.14 (-0.41%)

17:46
09/17/19
09/17
17:46
09/17/19
17:46
Hot Stocks
Uber to bring self-driving vehicles to Dallas, Texas »

Austin Geidt, head of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIVHY

Vivendi

$0.00

(0.00%)

, TCEHY

Tencent

$0.00

(0.00%)

17:46
09/17/19
09/17
17:46
09/17/19
17:46
Hot Stocks
Gaming executives launch VENN network for esports, other gaming content »

VENN, a startup …

VIVHY

Vivendi

$0.00

(0.00%)

TCEHY

Tencent

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDX

FedEx

$173.53

-0.14 (-0.08%)

17:43
09/17/19
09/17
17:43
09/17/19
17:43
Hot Stocks
FedEx EVP Carere: Global trade volumes to contract for first time since 2009 »

Says uncertainty over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 23

    Sep

  • 30

    Sep

  • 01

    Oct

  • 13

    Nov

FDX

FedEx

$173.53

-0.14 (-0.08%)

, AMZN

Amazon.com

$1,822.59

14.38 (0.80%)

17:39
09/17/19
09/17
17:39
09/17/19
17:39
Hot Stocks
FedEx summer challenges increased due to decision not to renew Amazon contract »

Says global macro…

FDX

FedEx

$173.53

-0.14 (-0.08%)

AMZN

Amazon.com

$1,822.59

14.38 (0.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 23

    Sep

  • 26

    Sep

  • 30

    Sep

  • 01

    Oct

  • 27

    Oct

  • 13

    Nov

SLCT

Select Bancorp

$10.98

-0.04 (-0.36%)

17:38
09/17/19
09/17
17:38
09/17/19
17:38
Hot Stocks
Select Bancorp announces approves new stock repurchase plan »

Select Bancorp, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEO

American Eagle

$16.55

-0.44 (-2.59%)

17:33
09/17/19
09/17
17:33
09/17/19
17:33
Initiation
American Eagle initiated  »

American Eagle initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

CACI

CACI

$216.89

0.91 (0.42%)

17:30
09/17/19
09/17
17:30
09/17/19
17:30
Upgrade
CACI rating change  »

CACI added to Conviction…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

ANF

Abercrombie & Fitch

$16.25

0.08 (0.49%)

17:29
09/17/19
09/17
17:29
09/17/19
17:29
Initiation
Abercrombie & Fitch initiated  »

Abercrombie & Fitch…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

FB

Facebook

$188.13

1.89 (1.01%)

, GOOG

Alphabet

$1,229.61

-1.75 (-0.14%)

17:28
09/17/19
09/17
17:28
09/17/19
17:28
Periodicals
U.S. antitrust regulators admit to 'squabbles' amid Big Tech probe, Reuters says »

U.S. regulators concede…

FB

Facebook

$188.13

1.89 (1.01%)

GOOG

Alphabet

$1,229.61

-1.75 (-0.14%)

AMZN

Amazon.com

$1,822.59

14.38 (0.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 24

    Sep

  • 26

    Sep

  • 27

    Oct

T

AT&T

$37.16

-0.16 (-0.43%)

17:25
09/17/19
09/17
17:25
09/17/19
17:25
Hot Stocks
AT&T sees wireless service revenue growth continuing in second half of 2019 »

Randall Stephenson,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

CDW

CDW

$113.91

0.94 (0.83%)

, TSS

TSYS

$132.86

-1.7 (-1.26%)

17:17
09/17/19
09/17
17:17
09/17/19
17:17
Hot Stocks
CDW to replace TSYS in S&P 500 at open on 9/23 »

Global Payments (GPN) is…

CDW

CDW

$113.91

0.94 (0.83%)

TSS

TSYS

$132.86

-1.7 (-1.26%)

GPN

Global Payments

$163.91

-2.21 (-1.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 13

    Nov

STBA

S&T Bancorp

$37.22

-0.17 (-0.45%)

17:16
09/17/19
09/17
17:16
09/17/19
17:16
Hot Stocks
S&T Bancorp board authorizes new $50M stock buyback »

The board of S&T…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDX

FedEx

$173.53

-0.14 (-0.08%)

17:12
09/17/19
09/17
17:12
09/17/19
17:12
Downgrade
FedEx rating change  »

FedEx downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 23

    Sep

  • 30

    Sep

  • 01

    Oct

  • 13

    Nov

NEXT

NextDecade

$6.30

-0.1 (-1.56%)

17:10
09/17/19
09/17
17:10
09/17/19
17:10
Initiation
NextDecade initiated  »

NextDecade initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TELL

Tellurian

$8.33

-0.1 (-1.19%)

17:10
09/17/19
09/17
17:10
09/17/19
17:10
Initiation
Tellurian initiated  »

Tellurian initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NLNK

NewLink Genetics

$1.90

-0.03 (-1.55%)

, MRK

Merck

$82.53

0.52 (0.63%)

17:06
09/17/19
09/17
17:06
09/17/19
17:06
Hot Stocks
NewLink Genetics says FDA accepts partnered BLA for ebola vaccine »

NewLink Genetics…

NLNK

NewLink Genetics

$1.90

-0.03 (-1.55%)

MRK

Merck

$82.53

0.52 (0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 20

    Sep

  • 24

    Sep

  • 27

    Sep

  • 02

    Oct

  • 03

    Oct

  • 29

    Oct

ESTC

Elastic

$93.80

2.15 (2.35%)

17:03
09/17/19
09/17
17:03
09/17/19
17:03
Hot Stocks
Elastic selected by New Zealands'The Warehouse for its customer service program »

Elastic N.V. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

TOL

Toll Brothers

$40.68

-0.11 (-0.27%)

17:00
09/17/19
09/17
17:00
09/17/19
17:00
Hot Stocks
Toll Brothers CEO sells 25,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WTR

Aqua America

$43.88

0.51 (1.18%)

16:56
09/17/19
09/17
16:56
09/17/19
16:56
Hot Stocks
Aqua America subsidiary to buy municipal wastewater system for $276.5M »

Aqua America announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INVH

Invitation Homes

$28.49

0.31 (1.10%)

16:54
09/17/19
09/17
16:54
09/17/19
16:54
Syndicate
Invitation Homes files to sell 44M shares of common stock for holders »

Morgan Stanley, Citigroup…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MODN

Model N

$28.43

0.275 (0.98%)

, IQV

Iqvia

$152.93

2.14 (1.42%)

16:49
09/17/19
09/17
16:49
09/17/19
16:49
Hot Stocks
Model N names Suresh Kannan as Chief Product Officer »

Model N (MODN) announced…

MODN

Model N

$28.43

0.275 (0.98%)

IQV

Iqvia

$152.93

2.14 (1.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 08

    Oct

  • 12

    Nov

GWW

Grainger

$291.76

-4.29 (-1.45%)

16:49
09/17/19
09/17
16:49
09/17/19
16:49
Conference/Events
Grainger management to meet with Buckingham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 23

    Oct

ACGL

Arch Capital

$40.89

0.33 (0.81%)

16:48
09/17/19
09/17
16:48
09/17/19
16:48
Conference/Events
Arch Capital management to meet with Buckingham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

TOL

Toll Brothers

$40.68

-0.11 (-0.27%)

16:47
09/17/19
09/17
16:47
09/17/19
16:47
Hot Stocks
Toll Brothers president Hartman sells over 40,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.